John C. Thomas

This profile gathers the share dealings of John C. Thomas across 4 companies, led by ImmunityBio, Inc., QLT Inc/BC and H-Cyte, Inc. Over a trading history stretching from 15 December 2014 to 4 January 2022, the count stands at 39 filings.

The open-market side counts 3 purchases for €12k alongside 20 sales for €1.7M. On balance, insiders were net sellers of €1.6M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 5 share grants and 6 option exercises. Since January 2022: 1 purchase and no sales on the market.

Half of the purchases are above €3,567 and half below.

The newest entry dates from 4 January 2022: an open-market purchase of €4,999, in Dogwood Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.